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Case presentations
Patient 1. A 46-year-old school teacher went to his family physician
because of a nose bleed. He had suffered from frequent headaches for
the previous 15 years and during the preceding 2 weeks had noticed an
accentuation of his usual pain as well as progressive blurring of his
vision. The physician documented the blood pressure at 260/150 mm Hg
and admitted the patient to the regional hospital.
On admission, the patient's blood pressure was 260/170 mm Hg; the
heart rate was 90 beats/mm. He had no dyspnea. Auscultation disclosed
an S3 gallop. In addition, he exhibited a grade-IV hypertensive retinop-
athy with papilledema. Electrocardiogram revealed left ventricular
hypertrophy. Laboratory tests revealed a serum creatinine of 119
mol/liter and proteinuria, 500 mg/24 hrs. Serum potassium and glucose
were normal. Left ventricular hypertrophy was confirmed by a chest
radiograph. The kidneys were normal in size and shape; computer-
assisted tomography and renal arteriogram showed no abnormality.
Initial therapy consisted of phentolamine and atenolol, which re-
duced his blood pressure to 200/120 mm Hg. Six years ago, the patient
was receiving captopril, 25 mg 3 times daily; minoxidil, 5 mg 3 times
daily; atenolol, 100 mg/day; hydrochlorothiazide, 50 mg/day; and amil-
oride, 5 mg/day. He was referred to the Centre Hospitalier Universi-
taire Vaudois for management of his blood pressure. Two months after
admission, he had stopped taking his minoxidil, and his blood pressure
was 194/132 mm Hg. The serum creatinine increased transiently to 146
tmo1/liter but fell to 110 molIliter. The addition of furosemide, starting
with 40 mg/day and increasing to 125 mg twice daily, induced a rebound
of the serum creatinine level to 130 molfliter, but his blood pressure
was 140/102 mm Hg 5 months after admission. Later, captopril was
replaced by enalapril, 20 mg/day, and an attempt was made to reduce
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the furosemide to 125 mg/day. As a result, his blood pressure rose again
to 172/122 mm Hg 5 years ago. Since then, the patient has been given
atenolol, 50 mg/day; enalapril, 10 mg/day; furosemide, 125 mg twice
daily; and allopurinol, 100 mg/day; the last was added 3.5 years ago
after an acute gouty attack. His blood pressures were close to normal,
for example, 138/94 mm Hg, except when furosemide was again
transiently reduced to 60mg/day, and the blood pressure rose to 160/120
mm Hg. One year ago, an ambulatory blood pressure recording
revealed a daytime average of 142/98 mm Hg. At the same time, an
echocardiogram revealed only a slight septal hypertrophy; the serum
creatinine was 114 j.smol/liter. The protein excretion had dropped to 67
mg/24 hrs. The patient has had no headaches since his hospitalization 6
years ago.
Patient 2. A 28-year-old white man noticed that his ankles were
swollen 2 months before consultation. He had been in good health
previously and had no history of a recent infection. He was working in
an office and was taking no drugs or medications.
Physical examination revealed marked edema of the ankles, eyelids,
and hands. His blood pressure in the seated position was 140/90 mm Hg,
his body weight was 63 kg, and his height was 168 cm.
Laboratory studies showed a serum creatinine of 90 smol/liter;
creatinine clearance was 120 mI/mm. Plasma electrolytes were normal.
Plasma proteins were 46 g/liter with 25 g/liter of albumin. Cholesterol
was 7.5 mmol/liter and triglycerides were 1.75 mmol/liter. The hema-
tocrit was 48.4 with a hemoglobin of 166 g/liter. Urinalysis revealed a
specific gravity of 1.020, 3 + protein (8.0 g/24 hr), 2+ blood with 20—25
red blood cells, and 1+ leukocytes with 6—8 white blood cells/high-
power field. The C3 fraction of complement was reduced to 9.4 mg/dl
(normal, 80—180 mg/dl); the C4 was normal. Antistreptolysins were
normal.
A renal biopsy demonstrated a mixed membranous and proliferative
glomerulonephritis. Combined therapy with prednisone (60 mg/day) and
cyclophosphamide (150 mg/day for 6 weeks) was initiated. The patient
did not respond to therapy; 5 months later the nephrotic syndrome
persisted; urinary protein excretion was 9.7 g/24 hrs. The serum
creatinine had increased to 105 zmol/liter. His body weight was still 63
kg, but the blood pressure had markedly increased to 180/100 mm Hg.
Atenolol (100 mg/day) reduced his blood pressure to 140/85 mm Hg.
During beta blockade, protein excretion remained at 8.5 g/24 hr, but the
serum creatinine rose to 115 smol/liter. Four months later, the patient
discontinued taking his antihypertensive medication because of side
effects.
His blood pressure was 160/110 mm Hg when enalapril, 10 mg/day,
was started 6 months after diagnosis. After one month of angiotensin
converting enzyme (ACE) inhibition, his blood pressure was 130/75 mm
Hg. His body weight was 61.5 kg and the edema had partially regressed.
Protein excretion had decreased to 5.4 g/24 hr, and the serum creatinine
was 100 mol/liter. The patient remained normotensive and asympto-
matic for more than one year.
Two years after the diagnosis of glomerulonephritis, the patient was
still receiving only an ACE inhibitor. His blood pressure was normal
and the urinary protein excretion was 4.6 g/24 hr. Despite the adequate
control of blood pressure and the seemingly lower protein excretion,
however, his renal function had decreased: the serum creatinine was
160 .tmol/liter, and the creatinine clearance was 50 mI/mm. Over the
next few months, his renal function continued to deteriorate. A second
course of prednisone and cyclophosphamide therapy slowed the pro-
gression of renal failure, but blood pressure control became more
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difficult. Furosemide and atenolol were added to enalapril to keep his
blood pressure values within the normal range. At the last followup,
serum creatinine was 215 smol/liter, protein excretion was 9.5 g/24 hr,
and the blood pressure was 140/90 mm Hg.
Discusssion
DR. HANS R. BRUNNER (Professor of Medicine, Hyperten-
sion Division and Cardiovascular Research Group, Centre
Hospitalier Unjversitaire Vaudois, Lausanne, Switzerland):
Renin of renal origin is the enzyme generally regarded as being
responsible for the generation of angiotensin I and II, both
within the circulation and within the kidney itself. Although
renin of "extrarenal" origin, that is, that found in tissues other
than the kidney, has been proposed as a major regulator of
cardiovascular homeostasis [1—6], it is likely that renin located
in non-renal tissues also originates in the kidney and circulates
to other sites [7]. Thus, the kidney is the point of departure for
understanding the cascade that leads to the formation of angio-
tensin I and II. Renal renin secretion varies considerably
depending on renal perfusion pressure, sodium balance, effer-
ent sympathetic nerve activity, etc. Angiotensin II levels thus
depend on the functional state of the kidney, which determines
the secretion of renin; in turn, the functional state of the kidney
possibly determines the degree of efficacy of an ACE inhibitor.
This relationship is rendered slightly more complicated by the
fact that angiotensin II reduces plasma renin levels via feedback
inhibition of renin release [8]. As a consequence, active renin
levels rise in response to ACE inhibition [9—11]. The magnitude
of this renin secretory response again is determined not only by
the level of angiotensin II but by the functional state of the
kidney.
The kidney is not only the source of circulating renin, which
determines the plasma concentration of angiotensin II, but it is
also one of the main targets of angiotensin II. Thus, angiotensin
II has some profound hemodynamic, glomerular, and tubular
effects that exert an important influence on renal function.
Renin therefore plays a very important double role, in which it
simultaneously reflects the functional state of the kidney and at
the same time importantly influences the function of this vital
organ. Consequently, ACE inhibitors also depend on the kidney
for their cardiovascular efficacy, while simultaneously exerting
profound influences on the kidney.
Because the kidney is a key organ in determining blood
pressure, be it via the renin-angiotensin cascade or via other
mechanisms [12], it is not surprising that many patients with
renal disease exhibit a high blood pressure. Today, such pa-
tients commonly are treated with ACE inhibitors to reduce their
blood pressure. While these agents can be quite efficacious,
particularly when given in combination with other drugs, some
important questions have been raised: Do ACE inhibitors exert
beneficial effects on the kidney that exceed the effect of blood
pressure reduction? Are ACE inhibitors beneficial to the kidney
even if blood pressure is not elevated?
The two patients presented today illustrate several relevant
points about the use of ACE inhibitors in patients with renal
disease: the management of hypertension in a patient with
moderate renal failure; the combination of ACE inhibitors with
other drugs, particularly diuretics; renin secretion in patients
with renal failure and the secondary augmentation of renin
secretion by ACE inhibition; the use of beta blockers to check
this secondary response; the beneficial effect of ACE inhibition
on renal function and the mediation of this effect by blood
pressure control versus ACE inhibition per se; ACE inhibition
and proteinuria; and the risks and untoward effects of ACE
inhibition in patients with renal disease. I will attempt to
address these points within the context of a broader discussion
of the interaction between the renal regulation of renin secre-
tion and the effects of ACE inhibition.
Renal effects of angiotensin II and of
converting enzyme inhibitors
Hemodynamic and vascular effects. Inhibition of the conver-
sion of angiotensin I to angiotensin II as well as direct antago-
nism of angiotensin's actions cause renal blood flow to increase
in animals in which the renin-angiotensin system is activated by
one of a variety of maneuvers [13, 14]. While negligible changes
were found in the sodium-replete state, we noted an important
redistribution of blood flow in sodium-deprived dogs in which
myocardial, total cerebral, and renal plasma flow increased
significantly when the renin-angiotensin system was inhibited
[15]. Similarly, captopril administration in normal humans
maintained on a low-sodium diet induces a highly significant
increase in renal blood flow [16]. Renal blood flow also in-
creases in response to converting enzyme inhibition in subjects
maintained on a high-sodium intake, but the net increase is
smaller, and a slightly higher dose of captopril is needed to
obtain that effect [16] (Fig. 1).
By what mechanisms does renal blood flow increase with
converting enzyme inhibition even in sodium-loaded subjects,
that is, in the absence of a stimulated renin-angiotensin system?
Is it possible that these changes are not due to a fall in
circulating angiotensin II but rather to an increase in bradyki-
nm, in prostaglanclin, or in some other factor [17, 18]? In
conscious dogs, intrarenal administration of captopril at doses
that selectively inhibit the renal vasoconstrictive action of
exogenous angiotensin I has no effect on renal vascular resis-
tance [19]. Systemic administration of the agent at markedly
higher doses produces a slight decrease in arterial pressure and
a 25% increase in renal plasma flow. Indomethacin does not
alter this renal vasodilating effect in sodium-replete dogs. In
animals infused with saralasin, captopril does not exert any
renal vasodilatory action [19]. These results taken together
favor a predominant role of angiotensin II in mediating the
effects of converting enzyme inhibition on renal hemodynam-
ics.
In patients with essential hypertension, converting enzyme
inhibition leads to renal vasodilation without any change in
glomerular filtration rate; as a consequence, filtration fraction
decreases [20]. The renal vasodilatory response to acute con-
verting enzyme inhibition actually appears to be potentiated in
patients with essential hypertension as compared with nor-
motensive subjects [16]. However, this potentiated renal re-
sponse to converting enzyme inhibition may be confined to a
substantial fraction of patients with essential hypertension
defined as "non-modulators" [21].
Which segment along the renal vasculature reduces its vas-
cular tone in response to converting enzyme inhibition? In the
1960s, angiotensin II was thought to have a direct effect on
afferent arteriolar resistance and it was thought that this effect
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was responsible for the autoregulation of renal blood flow and
glomerular filtration during changes in renal artery pressure
[221. Evidence against this hypothesis was provided by the
observation that the administration of an angiotensin H antag-
onist did not impair autoregulation of renal blood flow [23].
Studies in the late 1970s demonstrated that the renin-angioten-
sin system influences glomerular filtration rate through a vaso-
constrictor action of angiotensin on the efferent arteriole [241.
Most authors agree that converting enzyme inhibition causes
renal blood flow to increase while glomerular filtration rate
remains largely unchanged; as a result, filtration fraction is
reduced. These observations suggest that converting enzyme
inhibitors exert their effect predominantly on the efferent arte-
riole [25—301. However, micropuncture studies have shown
that, in a variety of physiologic conditions, afferent and efferent
resistances seem to change more or less in parallel [31]. Navar
and colleagues have developed an elegant computer model by
which they showed that changes in filtration fraction do not
necessarily indicate selective alterations in segmental vascular
resistance [32]. Therefore, converting enzyme inhibitors prob-
ably reduce afferent as well as efferent resistance. Their overall
effect, nevertheless, is an increase in renal blood flow without
any change in glomerular filtration rate.
That angiotensin II indeed constricts afferent as well as
efferent arterioles was recently shown directly by measurement
of the change in diameter of these arterioles [33, 34). Only after
Fig. 1. Effects of captopril on mean blood
pressure and renal flow in normotensive
subjects and in hypertensive patients during
salt restriction or repletion. A larger increase
in renal blood flow is observed in patients
with essential hypertension than in normal
subjects whether on a sodium restricted intake
or on a liberal sodium intake. (From Ref. 16.)
the administration of indomethacin was a clear dissociation
apparent between the effect of norepinephrine and that of
angiotensin II on the afferent arterioles such that only the
diameter change induced by norepinephrine was markedly
increased. This latter observation is somewhat in contradiction
with earlier reports by MacGiff and colleagues, who observed
that prostaglandins antagonize the renal arterial constriction
induced by aipha-adrenergic catecholamines as well as by
angiotensin II [351. The clinical relevance of prostaglandin
synthesis to modulate the actions of angiotensin II in the kidney
has been discussed extensively [36—38]. These authors have
postulated that "Whenever the vasoconstrictor agents angio-
tensin II, alpha adrenergic catecholamines, and arginine vaso-
pressin are augmented, renal function becomes prostaglandin
dependent." Thus it appears that, particularly under extreme
conditions, some of the shocks induced by angiotensin II to the
renal vasculature can be attenuated by increments in renal
PGE2. Interestingly, results obtained in the in-vitro blood-
perfused juxtamedullary nephron preparation indicate that the
effects of angiotensin II on the afferent, but not on the efferent,
arteriole can be blocked by the calcium-channel blocker vera-
pamil [34] (Fig. 2). This finding suggests that different mecha-
nisms might mediate angiotensin Il-induced constriction of pre-
and post-glomerular vessels.
Elegant studies in anesthetized dogs, in which renal perfusion
pressure was progressively reduced using an arterial clamp,
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demonstrated that increased renin secretion can maintain gb-
merular filtration rate in the presence of extremely low perfu-
sion pressure [24]. Indeed, glomerular filtration rate, as well as
filtration fraction, was well maintained at perfusion pressures as
low as 70 mm Hg, providing that the renin angiotensin system
remained intact. By contrast, in the presence of an angioteasin
II antagonist, glomerular filtration rate and filtration fraction fell
in parallel with the decrease in renal arterial pressure. Thus,
within the range of renal perfusion pressures commonly en-
countered in clinical settings, an intact renin system is required
for normal autoregulation of glomerular filtration rate to occur.
In accord with this conclusion, the administration of ACE
inhibitors to patients with low renal perfusion pressure often
results in a marked reduction in glomerular filtration rate.
Glomerular effects. As I noted earlier, angiotensin II can
affect glomerular filtration rate indirectly through its vascular
effects. Strong evidence also suggests that angiotensin II can
affect the glomerulus directly. Indeed, we have known since the
early l970s that angiotensin II receptors are present on renal
glomeruli [38]; their localization on gbomerular mesangial cells
was just discovered in the late l980s [39].
Mesangial cells possess intracellular microfilaments [401,
which contract when angiotensin II is added to isolated mesan-
gial cells in culture [411. Using these findings, Ausiello and
coworkers postulated that angiotensin II might reduce the
glomerular ultrafiltration coefficient, the product of the total
glomerular capillary filtering surface area, and the local hydrau-
lic conductivity [42]. In keeping with that hypothesis, the
• administration of an ACE inhibitor, together with a vasopressin
antagonist, normalized the reduced gbomerular ultrafiltration
coefficient in an animal model of hypertension in which the
renin-angiotensin system had been stimulated [43].
Angiotensin II can regulate glomerular ultrafiltration indi-
rectly through its effects on renal vascular resistance and flow,
and therefore on gbomerular capillary pressure, as well as
directly through its effects on the glomerular ultrafiltration
coefficient. Given that the glomerular mesangial cells also
synthesize PGE2, it is possible that the administration of ACE
inhibitors that can enhance PGE2 production could have addi-
tional effects on glomerular function [44, 45]. Whether such
stimulation of PGE2 synthesis by ACE inhibitors plays a major
role in glomerular function remains to be seen.
Effects on renin secretion. More than 25 years ago, Vander
and Geelhoed demonstrated that angiotensin II could inhibit
renin secretion [81. Given that this inhibitory effect of angioten-
sin II is seen in vitro in renal cortical slices [46], one can infer
that angiotensin II inhibits renin release by acting directly on
juxtaglomerular cells; thus, a direct negative feedback control
of renin release seems evident [47]. Recent experiments have
demonstrated that angiotensin II increases intracellular calcium
in mouse juxtaglomerular cells; this effect reduces renin secre-
tion [48].
In humans, both short- and long-term ACE inhibition in-
creases the concentration of enzymatically active renin in the
circulation [9—111. The active form of renin represents only part
of the total renin found in the circulation. Prorenin, which is the
inactive precursor of renin, is also present [49], and both active
and inactive forms of renin increase during ACE inhibition
[50—52]. However, the patterns of the change in the two types of
renin differ with time; immediately after the initial dose of the
ACE inhibitor is given, active renin rises at the expense of
inactive renin; with prolonged treatment, active and inactive
renin increase in parallel [53]. The stimulated release of active
renin due to ACE inhibition is responsible for a rise in plasma
angiotensin I levels [54]. The renin response to ACE inhibition
is blunted by beta-adrenoceptor blockade [55] as well as by
cyclo-oxygenase inhibition [56, 57]. The ability of ACE inhibi-
tion to elicit an increase in renin levels depends on the baseline
conditions of renin secretion. For instance, chronic salt and
water retention (with attendant hyporeninemia), induced by
several days of mineralocorticoid administration to normal
volunteers, completely abolishes the response [58].
The renin response to ACE inhibition has been of particular
interest to us. Several years ago, we observed that circulating
immunoreactive angiotensin II levels remained positively cor-
related with plasma renin activity, even during peak ACE
inhibition; this observation suggested that angiotensin II levels
were still under the control of plasma renin activity, even when
the latter was maximally inhibited [59]. At that time we could
not exclude the possibility of cross-reaction between angioten-
sin II and the high levels of circulating angiotensin I. Subse-
quently, considerable effort has been made to develop a specific
method for measuring the octapeptide, angiotensin II. By
separating the different angiotensin precursors and metabolites
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Fig. 2. Effect of verapamil on afferent and efferent arteriolar responses
to angiotensin II. Note that verapamil blocked the effect of the
angiotensin II on afferent arterioles (, n = 8) but not on efferent
arterioles (0, n = 6) (**F < 0.01). (From Ref. 34.)
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from the octapeptide using high-performance liquid chromato-
graphy, and then analyzing the samples with a highly sensitive
radioimmunoassay [60—62], it is now possible to demonstrate
that angiotensin II levels during ACE inhibition are determined
jointly by the amount of inhibitor present and by the amount of
active renin secreted in response to the ACE inhibition [63].
Furthermore, we also showed that the dose-response curve
relating a given ACE inhibitor to its effect on immunoreactive
angiotensin II levels is distorted by the augmented secretion of
renin [64]. Thus, despite the fact that increasing doses of a
converting enzyme inhibitor further decreased converting en-
zyme activity, angiotensin II levels did not fall proportionally,
apparently because active renin and plasma angiotensin I levels
rose progressively in response to higher doses of the inhibitor
(Fig. 3).
Of interest in this context is the observation that converting
enzyme inhibition in normal rats leads to an "upstream"
extension of immunostaining for renin along the afferent arte-
riole in the direction of the interlobular artery [65]. Not only is
the localization of immunostaining cells expanded, but the
fraction of juxtaglomerular cells containing renin also is in-
creased by ACE inhibition. Thus converting enzyme inhibition
appears to increase intrarenal renin synthesis, resulting in the
extension of renin synthesis upstream from the glomerulus
towards new sites in the blood vessels. Stella and colleagues
suggested that the renal nerves play a role in augmenting renin
release in response to ACE inhibition by increasing the sensi-
tivity of the juxtaglomerular cells to the negative feedback
action of angiotensin II [66]. Whatever the exact mechanism by
which ACE inhibition stimulates renin secretion, the compen-
Fig. 3. Acute effects of the initial (day 1) and
final (day 10) administration of 3 dfferen:
doses of the ACE inhibitor trandolapril on
blood angiotensin 1, plasma immunoreactive
angiotensin II, and the ratio of angiotensin
JI/angiotensin I in 7 normal volunteers. Note
that with the highest dose, plasma angiotensin
II levels appeared greater on day 10 than they
were on day 1. (From Ref. 64.)
satory rise in renin appears to be an important factor determin-
ing the net effect of the ACE inhibitor on the level of blood
pressure.
Tubular effects. As is well known, angiotensin II is a potent
stimulus for the secretion of aldosterone [67, 681 which, in turn,
induces sodium retention by the kidney. It is not surprising,
therefore, that the acute administration of a converting enzyme
inhibitor to normal humans induces a sodium diuresis [69]. This
effect might not depend on a fall in aldosterone levels, however,
because strong evidence exists that angiotensin II itself has
potent antinatriuretic and antidiuretic effects on the kidney [47,
70, 71].
In an effort to distinguish between the effect of reduced
plasma aldosterone concentration from the effect of reduced
angiotensin II generation, Hall and coworkers coupled the
administration of an ACE inhibitor with an infusion of aldoste-
rone in conscious dogs [72]. In dogs depleted of sodium, this
protocol resulted in a sustained and prolonged increase in
urinary sodium excretion. In fact, infusion of aldosterone for
several days did not prevent the diuresis or the relative hypona-
tremia caused by the administration of ACE inhibitors. In
contrast, the simultaneous administration of angiotensin II and
an ACE inhibitor did obviate these effects.
Somewhat at variance with these observations is the finding
in normal human volunteers treated with fludrocortisone ace-
tate; in this situation, converting enzyme inhibition does not
accelerate the escape from the salt-retaining effect of the
mineralocorticoid [58]; this finding suggests that other mecha-
nisms, such as a rise in renal perfusion pressure, play a
predominant role [73]. When animals are challenged to retain
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sodium, however, as following the abrupt introduction of an
extremely low-sodium diet, a rapid stimulation of the renin-
angiotensin system seems to be required for urinary sodium
excretion to be reduced and for circulatory homeostasis to be
maintained [14]; animals pretreated with a converting enzyme
inhibitor prior to dietary salt deprivation are unable to prevent
renal sodium loss, and sodium balance remains negative even
on the 6th day of a low sodium intake.
Hall and coworkers also examined the role of the renin-
angiotensin system in adaptation to varying sodium loads. They
varied sodium intake over a wide range in three groups of dogs:
a control, a group infused with angiotensin II at a fixed dose,
and a group given a converting enzyme inhibitor [74]. Although
all three groups were able to raise the urinary sodium excretion
when sodium intake was increased, only the control group did
so without a concomitant marked increase in arterial pressure.
In examining the relationship between mean arterial pressure
and urinary sodium excretion, it became apparent that main-
taining high levels of angiotensin II in the circulation greatly
impairs the kidney's capacity to excrete sodium, as manifested
by the higher-than-normal blood pressures that were needed to
achieve the requisite level of sodium excretion. Conversely,
blocking angiotensin II formation by inhibiting the converting
enzyme reduced blood pressure markedly, but this enabled the
kidney to achieve a balance between intake and output of
sodium at lower-than-normal arterial pressures, although a
certain blood pressure gain was necessary.
The direct tubular effects of angiotensin II have been re-
viewed by Navar et al [75]. Using stop-flow experiments in
dogs, Vander demonstrated that angiotensin II infusion in-
creases distal tubular sodium concentration [76]. Gertz, using
the shrinking droplet technique [77], and Leyssac, using occlu-
sion time experiments [78], suggested that angiotensin II sup-
presses proximal tubular sodium reabsorption. Navar and col-
leagues also demonstrated from a series of experiments that
ACE inhibition selectively reduces the reabsorptive rate of
proximal convoluted tubules [75]. The data of many investiga-
tors provide substantial support for the notion that endogenous
angiotensin II stimulates proximal tubular reabsorption. Studies
also suggest that angiotensin II is an important modulator of the
tubuloglomerular feedback system [79, 80]. Indeed, it appears
to be the synergistic effect of angiotensin II on tubular reab-
sorption and on tubuloglomerular feedback that permits
changes in angiotensin II to cause sustained effects on the
volume delivered out of the proximal tubule. These combined
actions of angiotensin II constitute the basis for a major
contribution made by the renin-angiotensin system in the sodi-
um-conserving mechanism that maintains vital homeostasis
during low sodium intake and during other situations in which
extracellular volume is reduced.
Angiotensin II receptors have been found on both the brush
border and basolateral membranes of proximal tubular epithe-
hum [8 1—831. The potential biologic significance of these recep-
tors has been demonstrated by a variety of studies that have
investigated the signaling mechanisms to which they are cou-
pled in the proximal tubular epithelium [83]. In addition, the
specific angiotensin II receptor antagonist DuP 753 recently has
been shown to exert a powerful inhibitory effect on bicarbon-
ate, chloride, and water absorption in the SI subsegment of the
proximal convoluted tubule [84]. Considerable evidence exists,
therefore, that angiotensin II can exert a marked direct influ-
ence on proximal sodium reabsorption and that this influence
can be attenuated either by reducing levels of circulating
angiotensin II or by inhibiting its action at the receptor level.
Renin, converting enzyme inhibition, and blood pressure
The renin-angiotensin system appears to contribute impor-
tantly to the development of hypertension in some patients with
chronic renal failure [85]. In a majority of patients, however,
impaired sodium handling by the kidney appears to play the
major role [86]. Indeed, plasma renin activity is often normal or
even low in this condition [87, 88]. Some have suggested that
the renin secretion, although not elevated in absolute terms,
may be inappropriately high in relation to the associated sodium
retention [87, 88]. Moreover, plasma renin activity might not
closely reflect the amount of angiotensin II generated locally
within the kidney [89]. Nevertheless, ACE inhibitors given as
monotherapy for hypertension in patients with renal disease
normalize blood pressure less frequently than when these
agents are administered to hypertensive patients who have
normal renal function [90, 91].
In hypertensive patients with end-stage renal failure, hemo-
dialysis together with ultrafiltration of extracellular fluid usually
is effective in reducing blood pressure from elevated to normal
levels. Patients whose hypertension does not respond to such
sodium depletion tend to have inappropriately high plasma
renin activity [92]. In such patients, chronic ACE inhibition
offers an effective and attractive alternative to bilateral ne-
phrectomy [93, 94]. Also, ACE inhibitors are potentially useful
in some patients who develop hypertension after renal trans-
plantation [95]. The problems associated with the treatment of
post-renal-transplant hypertension with ACE inhibition have
been reviewed elsewhere [96]. Before the use of cyclosporine in
the treatment of transplant recipients, blood pressure often
could be reduced markedly by ACE inhibitors. In patients who
were destined to reject their kidneys, the antihypertensive
effect of ACE inhibition tended to be blunted, and the antici-
pated increase in renal blood flow was minimal. Of considerable
interest is the finding that a fall in GFR during ACE inhibition is
a strong indicator of the presence of renal artery stenosis in the
transplanted kidney [97].
In patients treated chronically with cyclosporine, circulating
renin levels are consistently lower than in patients treated with
conventional immunosuppressive therapy, probably because ol
extracellular fluid volume expansion [98]. Some authors have
suggested, alternatively, that intrarenal activation of prorenin h
defective [99]. In contrast, short-term administration of cyclo-
sporine, at least in the rat, stimulates renin release [100]:
consistent with this finding, cyclosporine stimulates renin re-
lease by isolated rat juxtaglomerular cells [101]. Acute convert-
ing enzyme inhibition usually is not effective in reducing blood
pressure in transplant patients treated with cyclosporine. Ir
some instances, however, treatment with an ACE inhibitor foi
more than one year is associated with a progressive decrease it
mean arterial pressure without changes in renal plasma flow oi
GFR [96]. Thus, even in patients treated with cyclosporine
chronic blockade of the renin-angiotensin system is sometimes
beneficial.
Patients with renovascular hypertension typically are resis-
tant to conventional antihypertensive agents [102]. Given theii
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unique ability to prevent the generation of angiotensin II, ACE
inhibitors offer the theoretical advantage of interfering specifi-
catty with the principal pathogenetic mechanism responsible for
renovascular hypertension [103]. Indeed, ACE inhibitors have
exhibited great efficacy in controlling blood pressure in animal
models of [104—106], as well as in patients with [107—1131,
renovascular hypertension. Thus, captopril alone or combined
with diuretics successfully controlled the blood pressure of 90%
of 160 patients with renovascular hypertension [107]. In one
prospective, double-blind study, blood pressure reduction ob-
tained with enatapril plus hydrochlorothiazide was compared
with that obtained with conventional triple therapy using hydro-
chiorothiazide, timolol, and hydralazine [114]. The degree to
which systolic blood pressure was reduced, as well as the
fraction of patients whose blood pressure was normalized, was
significantly greater in patients treated with the converting
enzyme inhibitor. Unfortunately, as I shall discuss later, the
treatment of renovascular hypertension with converting en-
zyme inhibitors carries a risk for potential deterioration of renal
function.
In addition to interrupting the peripheral arterial constriction
mediated by angiotensin II, ACE inhibitors might exert an
additional antihypertensive effect in patients with renovascular
hypertension by vasoditating the contratateral, intact kidney
[115]. The administration of a converting enzyme inhibitor
actually might reverse the angiotensin-induced ability of the
non-clipped kidney to autoregulate filtration rate in response to
acute reductions in renal perfusion pressure. That angiotensin
II may play an important role in the renal vasoconstriction
observed during the development of genetic hypertension has
been suggested by several authors [116], and evidence exists
that the renal vasoconstriction plays an important role in the
pathogenesis of this type of hypertension.
The antihypertensive activity of ACE inhibitors is usually
increased greatly by the concomitant administration of a di-
uretic [117—121]. Commonly, a very low dose of a diuretic
suffices to reduce blood pressure when combined with an ACE
inhibitor [1221. In keeping with the observation, hypertensive,
salt-depleted patients with maximal blockade of angiotensin II
generation are much more likely to develop hypotension than
are hypertensive, salt-repleted patients with similar blockade of
angiotensin II production [88, 123]. Thus, patients treated with
ACE inhibitors who tolerate high doses of potent diuretics
without developing signs of hypovolemia or hypotension prob-
ably require such doses. Conversely, the use of high doses of a
loop diuretic without concomitant ACE inhibition probably is
unwise, because the compensatory rise in renin secretion that
would occur might sustain an elevated blood pressure, thus
masking the presence of hypovolemia [124].
Combining a beta-blocker with an ACE inhibitor in the
treatment of hypertension could be regarded as lacking a
rational basis, but evidence exists that such a combination is
clearly beneficial in some hypertensive patients [55, 119, 125,
126]. One can speculate that this beneficial effect reflects the
ability of renal beta adrenoceptor blockade to blunt the hyper-
reninemia that occurs in response to ACE inhibition [55].
With the exception of captopril and lisinoprit, all ACE
inhibitors currently in use are administered in a pharmacologi-
cally inactive ester form. After absorption, hydrolysis is re-
quired before they can exert their pharmacologic effect. All
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Fig. 4. Relationship between area-under-the-curve (A UC) for enalap-
rilat concentration over a 48-hour period after the first dose of enalapril
maleate as a function of creatinine clearance. (From Ref. 130.)
currently used ACE inhibitors, including captoprit, enalapril,
lisinopril, quinapril, cilazapril, and ramipril, are excreted by the
kidney. As one might expect, therefore, the pharmacokinetics
of these substances are influenced to a great degree by the level
of renal function, and some precautions must be taken when
renal excretory function is impaired [127]. In subjects with
normal renal function, these agents generally are excreted in a
biphasic fashion. The initial, faster phase is thought to represent
renal clearance of the free compound, whereas the later, more
prolonged phase is thought to reflect the initial binding to, and
subsequent dissociation of, the compound from its target en-
zyme [128, 129].
Thus, in patients with impaired renal function who are given
repeated doses of enalapril, plasma enalaprilat levels increase
as a function of decreasing levels of creatinine clearance. In
fact, a close inverse correlation exists between the area under
the curve" of enataprilat plasma levels over 48 hours and
creatinine clearance (Fig. 4) [130]. In patients treated with
dialysis, steady-state conditions are not reached even after one
week of enalaprit administration; dialysis clearance of enatap-
rilat averages approximately 68 mt/mm [130].
The results obtained with other ACE inhibitors are similar. A
close linear correlation exists between clearance of quinapril
and creatinine clearance, and an inverse relationship exists
between the duration of 90% ACE inhibition and creatinine
clearance [127]. Some of the newer compounds, such as fos-
inopril, benazepril, and spirapril, exhibit additional non-renal
routes of excretion, thus presenting a potential advantage for
patients with renal failure [131, 132].
The pattern of blood pressure reduction seen after the initial
administration follows the time course of changes in angiotensin
II levels, falling as expected and returning to baseline within a
few hours, depending on the half-life of the particular drug [11].
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With prolonged administration of an ACE inhibitor, however, a
clear dissociation is observed between the duration of ACE
inhibition and the duration of blood pressure reduction [133].
This phenomenon appears to become more pronounced the
longer the duration of the treatment, such that angiotensin II
levels tend to fall at the time of the drug's peak effect and to
return to baseline before administration of the next dose, while
blood pressure remains low throughout, varying relatively little.
This observation has been interpreted by many as evidence that
ACE inhibitors reduce blood pressure by mechanisms indepen-
dent of angiotensin II [17]. This pattern of blood pressure
response is, however, consistent with that seen after prolonged
administration of many other antihypertensive drugs [134] and
might be related less to the mechanism of action of the
antihypertensive drug than to changes that take place in the
arterial wall after prolonged antihypertensive therapy.
Renal protection and proteinuria
As is well known, rats with subtotal renal ablation of suffi-
cient magnitude progress inexorably to renal failure and pro-
teinuria associated with progressive glomerular sclerosis [135,
136]. Several studies have shown that the remnant nephrons
develop increased glomerular capillary pressure and plasma
flow that result in increased single-nephron glomerular filtration
rate and in progressive glomerular injury [137—140]. Other
investigators have focused on the glomerular hypertrophy
rather than the glomerular capillary hypertension as being
responsible for progressive glomerular sclerosis [141].
Converting enzyme inhibitors have been shown to exert a
protective effect on glomerular function in the remnant kidney
model [142]. This effect is associated with a normalization in
glomerular capillary pressure and presumably results from an
attenuation of angiotensin II's effect on the efferent and afferent
arterioles of the glomeruli. Some [142, 143] but not all [144]
authors have concluded that ACE inhibitors are more effica-
cious in preventing progressive renal functional deterioration in
this model than is conventional, triple antihypertensive therapy
despite equivalent blood pressure reduction [142, 143].
How relevant these observations are for progression of renal
functional impairment in humans is a major unanswered ques-
tion. Several investigators have suggested that the loss of a
critical amount of functional renal mass in patients with chronic
renal insufficiency sets the stage for the development of pro-
gressive renal failure [145, 1461. Other authors however, have
remained skeptical, emphasizing the disparity in the progres-
sion of renal deterioration in individual patients [147]. Among
the variables that appear to be most important in fostering the
progression of renal failure is the presence of hypertension [146,
148]. Indeed, it has long been recognized that untreated hyper-
tension can markedly accelerate [1491 and that control of blood
pressure with antihypertensive therapy can slow the progres-
sion of renal failure [150, 151].
Not surprisingly, the potential role of ACE inhibitors for this
purpose has received considerable attention. Several studies
designed to assess the short-term effect of converting enzyme
inhibitors on renal function in patients with renal disease and
proteinuna generally have concluded that these agents reduce
filtration fraction and proteinuna [152—156]. More interesting,
of course, are studies of the long-term effects of ACE inhibitors.
When the long-term use of converting enzyme inhibitors was
compared retrospectively with conventional antihypertensive
treatment in patients with similar initial serum creatinine levels
(>2.5 mg/dl), the group treated with ACE inhibitors exhibited
a significantly lower serum creatinine level after a 2-year course
of therapy despite identical control of blood pressure [157].
Other studies have assessed the rate of progression of renal
failure after switching patients from standard triple therapy to
converting enzyme inhibition and have reported complete stabi-
lization of renal function 3 years after the therapeutic change
was made [158].
The effect of ACE inhibitors on progression of renal disease
also has been compared with that of calcium channel blockers.
These latter compounds have quite different effects on glomer-
ular hemodynamics. By decreasing the resistance exclusively in
the afferent arteriole, calcium channel blockers transmit sys-
temic pressure to the glomerular capillaries. As a consequence,
they potentially interfere with autoregulation of glomerular
filtration rate and renal blood flow [159—161]. Surprisingly,
some authors comparing a calcium channel blocker with con-
ventional triple therapy have found after a followup of 17
months that the calcium channel blocker could slow the pro-
gression of renal failure [162]. Indeed, from their intrarenal
hemodynamic effects alone, one would predict that calcium
channel blockers cannot exert a protective effect against progres-
sive glomerular injury. When rats with progressive renal failure
due to subtotal nephrectomy were treated with one or the other
of these regimens, only those receiving a converting enzyme
inhibitor exhibited lower serum creatinines than did untreated
controls. Moreover, only those receiving a converting enzyme
inhibitor had significantly reduced glomerular sclerosis scores
[163]. Other studies have clearly established that the adminis-
tration of ACE inhibitors can reduce proteinuria in patients with
non-diabetic renal failure [152, 164]. Reduced proteinuria, how-
ever, does not guarantee that progression to renal failure will be
arrested, Furthermore, long-term improvement in renal func-
tion has been reported after relatively short-term, but very
strict, blood pressure control in hypertensive patients with
nephrosclerosis, whether or not converting enzyme inhibitors
were included in the antihypertensive regimen [165].
Diabetic nephropathy might be a special case worthy of
particular attention. Eaiiy in the development of diabetes
mellitus, glomerular filtration rate is thought to be increased
[166, 167]. Rats with experimental diabetes develop progressive
albuminuria and glomerular injury [168—170]. In a long-term
study in diabetic rats, administration of an ACE inhibitor
prevented the development of albuminuria and glomerular
injury; antihypertensive therapy using a combination of three
drugs was much less effective [170]. Several authors have
reported that the administration of ACE inhibitors to diabetic
patients reduces proteinuria [171, 172]. Two studies have ex-
amined whether ACE inhibition retards the rate of decline in
glomerular filtration rate in patients with diabetic nephropathy
[173, 174], and both reported a salutary effect after 2 years of
treatment. When 16 proteinuric patients with diabetic glomer-
ulopathy were treated for 90 days with an ACE inhibitor,
proteinuria was reduced without lowering renal plasma flow or
glomerular filtration rate. Using differential solute clearances as
a measure, Meyer et al showed that ACE inhibition improved
selectivity of the glomerular membrane [175] (Fig. 5). When the
effects of placebo, captopril, and nifedipine treatment were
C)
C)
C)
C)
C)0
z
C)
•1
C)
C)
C0
C)
LL
100
50
Fig. 6. Effect of treatment by placebo, nfedipine, and captopril on the
urinaly excretion of albumin in insulin-dependent, normotensive dia-
betic patients. Control, open bar; treatment, closed bar. (From Ref.
176.)
compared in normotensive patients with incipient diabetic
nephropathy, nifedipine administration increased proteinuria
whereas captopril treatment reduced it [176] (Fig. 6). However,
in hypertensive, type-Il diabetic patients with nephropathy,
both captopril and another calcium channel blocker, nicar-
dipine, were associated with reduced urinary albumin excretion
[177]. The discrepant results obtained by these two latter
studies might be related to the differences in the level of blood
pressure in the patients studied. Indeed, the latter study dem-
onstrated a close correlation between the blood pressure reduc-
tion and urinary albumin excretion (Fig. 7). Thus, when blood
pressure is reduced in hypertensive diabetic patients, regardless
of the means employed, it is likely that albuminuria will fall and
that presumably the progression of renal functional deteriora-
tion will be retarded. An important question remaining to be
answered is whether renal functional deterioration in normoten-
sive diabetic patients can be prevented by the administration of
an ACE inhibitor without affecting systemic blood pressure.
Renal risks of ACE inhibition
Isolated case reports have implicated ACE inhibitors as a
cause of interstitial nephritis and of renal glucosuria [178], but
the extreme rarity of these reports, given the millions of
patients treated with these agents, suggests that the risk of these
complications is negligible.
Somewhat more alarming were the early reports of membra-
nous glomerulopathy occurring in patients treated with high
doses of captopril [179]. A collaborative study group estab-
lished to review the evidence confirmed the diagnosis in 2
captopril-treated patients [180]. However, it became evident
that the existence of captopril-induced membranous glomeru-
lopathy had to be viewed with great caution, as pretreatment
biopsy specimens were rarely available for histologic analysis.
In one patient who had been biopsied before captopril was
administered, membranous glomerulonephritis also was found.
Concern about this complication has receded since the recom-
mended dose of captopril was reduced considerably from that
used originally.
A major theoretical concern in using ACE inhibitors as
antihypertensive agents in patients with normal or decreased
renal function is the risk of inducing renal functional impair-
ment. In a retrospective analysis of 6737 hypertensive patients
treated with captopril for 1 to 12 months, the patients with
pre-treatment serum creatinine levels less than 1.5 mg/dl expe-
rienced a slight increase in serum creatinine during captopril
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treatment. Patients who had higher pre-treatment levels expe-
rienced a progressive reduction in serum creatinine during
captopril therapy [91]. These data are quite reassuring and
suggest that ACE inhibitors can be administered safely to
patients with and without renal insufficiency.
Reversible acute renal failure has been reported frequently
following ACE inhibition in patients with renal vascular hyper-
tension [107, 181—184]. This complication appears to occur,
however, only when renal perfusion is critically compromised.
Such compromise can be present in patients with severe bilat-
eral renal artery stenosis and in those with a significant nar-
rowing of the renal artery of a solitary kidney [181]; it also can
occur in hypertensive renal transplant patients [95, 96, 185].
The precise incidence of ACE-inhibitor-induced acute renal
failure in renal hypertension has not been determined. Hollen-
berg, in a review of 269 patients treated with captopril for
renovascular hypertension, found only 8 cases of renal failure
[107]. In a prospective study, 10 of 49 patients with renovascu-
lar hypertension treated with enalapril and hydrochiorothiazide
experienced an increase in serum creatinine levels of more than
0.3 mg/dl [114]. The incidence of renal failure certainly is higher
in patients with bilateral renal artery stenosis, but clearly not all
patients with this form of renovascular hypertensive disease
will experience a deterioration in renal function. Thus, as long
as renal function is monitored closely, particularly within one
week following initiation of therapy, no absolute contraindica-
tion exists for the use of ACE inhibitors in patients with
renovascular hypertension.
Some patients who had experienced a decrease in glomerular
filtration (GFR) with one ACE inhibitor have been rechallenged
with another ACE inhibitor; again GFR fell, demonstrating that
the effect on renal function is related to ACE inhibition per se,
and not to a nonspecific effect of any of the compounds [181,
186].
The importance of renal perfusion pressure in preserving
glomerular filtration during antihypertensive therapy has been
demonstrated in a study of 8 patients with bilateral, and another
8 patients with unilateral, atherosclerotic renovascular hyper-
tension [187]. In patients with bilateral renal artery lesions, a
decrease in systemic blood pressure induced by the infusion of
sodium nitroprusside resulted in a progressive fall in renal
perfusion and renal function. In patients with unilateral steno-
sis, a similar decrease in arterial blood pressure had no effect on
overall renal function. In a second study in patients with
unilateral renal artery stenosis, the same authors found that
glomerular filtration rate decreased when blood pressure was
lowered with an ACE inhibitor but remained unchanged when a
similar blood pressure reduction was induced by sodium nitro-
prusside [27]. These authors also observed occasional episodes
of ACE-inhibitor-induced renal failure in the absence of a
significant reduction of systemic blood pressure.
These results provide evidence suggesting that angiotensin II
plays a crucial role in regulating intraglomerular pressure and
glomerular filtration. The parameters that appear to determine
the renal response to ACE inhibitors in patients with renovas-
cular hypertension have been reviewed [188]. In addition to the
level of systemic blood pressure and the degree of activation of
the renin-angiotensin system, the severity of the stenosis, the
function of the contralateral kidney, and the phase of hyper-
tension are additional elements that should be considered in any
estimate of an individual's risk of developing acute renal failure
during ACE inhibition therapy.
Conclusions
Converting enzyme inhibitors, administered alone or in com-
bination with diuretics or other antihypertensive agents, have
proven to be very effective in the treatment of hypertension
associated with renal disease. Indeed, they have become a
mainstay in the treatment of renal hypertension because of their
proven efficacy and tolerability, While effective in reducing
blood pressure in most patients, they also exert profound and
generally welcome effects on intrarenal hemodynamics and on
glomerular and renal tubular function. Less welcome is their
indirect stimulation of renin secretion. Whether the net effect of
their antihypertensive and other actions can protect the kidney
from progressive functional deterioration remains to be clari-
fied. Effective pharmacologic control of blood pressure is, at
present, the only therapeutic measure known to protect the
kidney from functional deterioration. The ACE inhibitors are
effective as antihypertensive agents, and they might offer an
additional degree of protection that other antihypertensive
therapies cannot.
Questions and answers
Da. JORDAN J. COHEN (Dean of Medicine, State University
of New York at Stony Brook, Stony Brook, New York): Is
anything known about the mechanism whereby ACE inhibitors
affect the glomerular pore size? Is there any evidence that ACE
inhibitors of varying molecular structure have different effects
on glomerular pore size?
DR. BRUNNER: The mechanism by which ACE inhibitors
affect the glomerular pore size is most likely a reversal of the
angiotensin Il-induced contraction of the glomerular mesangial
cells. I do not believe that anything is known about differential
effects by ACE inhibitors with varying molecular structure.
DR. COHEN: Does severe salt restriction predispose one to
hypotension from ACE inhibitors as does high-dose furo-
semide?
DR. BRUNNER: There is little doubt that a strict low-sodium
diet can predispose one to severe ACE-inhibitor-induced hypo-
tension. However, it is often difficult to maintain a strict
low-sodium diet for a long time. Moreover, particularly if renal
function is somewhat reduced, a degree of sodium depletion
sufficient to reduce blood pressure often can be achieved only
with the administration of furosemide. Surprisingly, the occa-
sional patient needs—and tolerates—high doses of furosemide
together with ACE inhibition despite apparently normal renal
function.
DR. YVES PIRsON (Chef de Service Associé, Renal Unit,
Cliniques Universitaires St.-Luc, Brussels, Belgium): Could
you comment on the mechanisms of the antiproteinuric effect of
ACE inhibitors? Is this effect purely hemodynamic? Can ACE
inhibitors decrease the fractional excretion of albumin?
DR. BRUNNER: The mechanism is definitely not just hemo-
dynamic, although the hemodynamic effects of ACE inhibition
also must play a role. The change in pore size could contribute
to the reduced proteinuna. The fractional excretion of protein
certainly is reduced. This is probably also the case for fractional
excretion of albumin. A decrease in GFR is not needed to
reduce the proteinuria.
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DR. LEENDERT A. VAN Es (Professor of Medicine, Depart-
ment of Nephrology, Leiden University Hospital, Leiden, The
Netherlands): In your studies on the antiproteinuric effect of
ACE inhibitors, did the decrease in protein excretion closely
follow the hemodynamic effects?
DR. BRUNNER: The proteinuria decreases after ACE inhibi-
tion even if the blood pressure remains unchanged. Intrarenal
hemodynamics usually are not measured in these clinical stud-
ies. The ACE-inhibitor-induced changes in intrarenal hemody-
namics are immediate, whereas the reduction in proteinuria can
take days or weeks. This pattern suggests that the antiproteinu-
nc effect of ACE inhibitors is directly related neither to
systemic nor to intrarenal hemodynamics.
DR. GIUSEPPE REMUZZI (Head, Laboratory of Kidney Dis-
ease, Mario Negri Institute, Bergamo, Italy): Studies from Dr.
Bryan Myers' group and our own have indicated consistently
that ACE inhibitors improve glomerular size-selective proper-
ties by reducing the mean dimensions of large, nonselective
hypothetical pores. This phenomenon might be independent of
hemodynamic changes and can explain the reduction in protein-
uria.
DR. COHEN: Do these studies give us any insights into the
mechanism by which ACE inhibitors affect the pore size of the
glomerular capillary filter?
DR. REMuzzI: The mechanism likely is linked to the inhibi-
tion of angiotensin II's biologic activity. Angiotensin Ii induces
mesangial cell contraction, so its inhibition might result in
conformational changes of the mesangial cell that may well
modify pore dimensions.
DR. NIcoLAos E. MAD lAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts): In your
studies, does the antiproteinuric effect of ACE inhibitors and
their influence on the porosity of the glomerular capillary filter
depend on the state of the sodium balance?
DR. REMUZZI: Preliminary data from our laboratory seem to
exclude the possibility that the state of sodium balance plays a
major role.
DR. RANDALL M. ZUSMAN (Director, Division of Hyperten-
sion and Vascular Medicine, Massachusetts General Hospital,
Boston, Massachusetts): Is there an endogenous ACE inhibi-
tor?
DR. BRUNNER: I am not aware of any, but since you have
asked the question, you might know more.
DR. ZUSMAN: A preliminary report on the isolation of an
endogenous angiotensin-converting-enzyme inhibitor was pre-
sented at the First International Conference on ACE inhibition
in London in 1989. I have not seen the subsequent publication
of a full manuscript with the details of the inhibitory substance,
however. Given the nature of the renin-angiotensin-aldosterone
cascade, and the multiple points of regulation, I would not be
surprised to learn that endogenous substances that inhibit the
angiotensin converting enzyme exist and that they play an
important role in regulating the expression of this system at the
tissue level.
DR. BRUNNER: I wonder how good the evidence is if this has
not been published since 1989.
DR. KARL M. KOCH (Professor of Medicine, Hannover
Medical School, Hannover, Germany): My question concerns
the experience with ACE inhibitors in transplant patients.
Could you speculate on what level or by what mechanism
cyclosporine interferes with the effects of ACE inhibitors?
DR. BRUNNER: The situation in renal transplant patients is
very complex. They are treated not only with cyclosponine but
also with steroids. In addition, they often exhibit some degree
of sodium retention connected with acute or chronic rejection.
In the presence of this complex situation, it is not surprising
that the clinical results with ACE inhibitors are confusing. I'm
afraid I can't answer your question definitively.
DR. BRUNO BAGGIO (Associate Professor of Nephrology,
Institute of Internal Medicine, Division of Nephrology, Pa-
dova, Italy): Is it possible that the contradictory effects of the
converting enzyme on the renal hemodynamics and on the
proliferation of the glomerular epithelial and mesangial cells
depend on the renal hormonal state of each patient, in particu-
lar, on the activity levels of the kinins and the prostaglandin
systems, which are also influenced by the converting enzyme?
DR. BRUNNER: That is really Dr. Zusman's area. I have
presented most of the data focusing on angiotensin II because
we believe that it is rather the reduction of angiotensin II that
represents the predominant effect of ACE inhibitors. Dr. Zus-
man has published a lot of evidence suggesting that bradykinin
or prostaglandins are important principles responsible for the
action of ACE inhibition. Dr. Zusman, could you comment on
this issue?
Da. ZUSMAN: In contrast to other angiotensin-converting-
enzyme inhibitors, captopril has effects that exceed the ex-
pected response to inhibition of the generation of angiotensin II.
These effects are mediated by the stimulation of endogenous
prostaglandins. Our own studies with renomedullary interstitial
cells in tissue culture have demonstrated the stimulatory effect
of captopnil on the synthesis of prostaglandin E2 by these cells.
This effect is mediated by the stimulation of arachidonic acid
release from the phospholipid storage pool. Similarly, captopril
increases prostanoid biosynthesis by vascular endothelial cells
and renal glomeruli [reviewed in Ref. 1891. The stimulation of
prostanoid synthesis has not been observed in similar experi-
ments using enalapril, and the effect of captopnil appears to
depend on the presence of the sulfhydryl group as part of the
captopnil molecule [189]. To further investigate the non-renin-
dependent effects of captopnil, we recently compared the he-
modynamic effects of captopril and a renin inhibitor in human
subjects on salt-restricted and salt-replete diets [1901. Under
conditions of salt-depletion, the renin inhibitor reduced the
blood pressure of the 6 human subjects we studied. We ob-
served no hemodynamic effect, however, when these individu-
als were on a salt-replete diet. In contrast, captopril signifi-
cantly lowered the blood pressures of these subjects, regardless
of their sodium intake. The fall in plasma angiotensin II levels
during renin inhibition and ACE inhibition were comparable as
measured by Dr. Brunner's colleague, Dr. Jurg Nussberger,
who collaborated with us on this project. I believe these results
are consistent with a hemodynamically important role for
captopril-stimulated prostaglandin biosynthesis in the blood-
pressure-lowering effect of this compound [1901.
DR. BRUNNER: The problem with the observations by Dr.
Zusman is that although captopnil and enalapril seem to have
different effects on prostanoid synthesis in vitro, when exam-
ined clinically no evidence exists suggesting an increased
vasodilating or blood-pressure-lowering effect of captopril as
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compared with enalapril. This in itself sheds doubt on the
hemodynamic relevance of the captopril-stimulated prostaglan-
din E2 synthesis. Moreover, as to the study mentioned by Dr.
Zusman in which Dr. Nussberger from our group has collabo-
rated, it is also subject to a different interpretation. First of all,
these were acute studies. The renin inhibitor was infused for 60
minutes only, whereas the captopril effect lasts much longer.
These are agents with different pharmacokinetics and different
mechanisms of action, even within the renin-angiotensin cas-
cade. Both drugs reduced blood pressure in the salt-depleted
subjects. In the salt-replete subjects, indeed captopril reduced
blood pressure by 5 or 6 mm Hg within the first 60 minutes,
whereas the renin inhibitor reduced it by approximately 3 mm
Hg. This is a small difference on which to build a hypothesis.
Furthermore, the antihypertensive effect of the angiotensin II
antagonist Losartan (DuP 753) is smaller than that of enalapril
on the first day of administration. On the 5th day, however,
administration of both drugs reduced blood pressure similarly
[191]. Thus, many more, and particularly long-term, studies are
needed to demonstrate that the predominant mechanism of
ACE inhibitors in reducing blood pressure is independent of
angiotensin II.
DR. MADIAS: Is there additional evidence that the various
ACE inhibitors differ in terms of prostaglandin-stimulatory
effects?
Da. BR1JNNER: You have heard Dr. Zusman report his data.
In my opinion, most converting enzyme inhibitors have similar
prostaglandin stimulatory effects.
DR. MADIAs: Does chronic ACE inhibition result in adjust-
ments in the level of plasma angiotensinogen, that is, the renin
substrate?
DR. BRUNNER: Chronic converting enzyme inhibition de-
creases circulating plasma angiotensinogen levels. This de-
crease probably is due mainly to increased substrate consump-
tion by the high renin levels.
DR. CHRISTOPHER G. WINEARLS (Consultant Nephrologist,
Renal Unit, Churchill Hospital, Oxford, United Kingdom):
What is the risk of producing irreversible renal failure when one
gives an ACE inhibitor to a patient with a single kidney
harboring renal artery stenosis or to a patient with bilateral
renal artery stenosis?
DR. BRUNNER: There have been some isolated reports of
irreversible renal failure after treatment with an ACE inhibitor
in these situations. One has to keep in mind that even if this
happens, it is difficult to know whether the irreversible renal
failure is due to ACE inhibition per se or whether it is related to
the progressive nature of renal artery stenosis, particularly if
this is of the arteriosclerotic type. Furthermore, it is known that
recovery from renal failure can take weeks or months.
DR. PHILIPPE JAEGER (Director, Policlinique medicalé, Ho-
pital de l'Ile, Berne, Switzerland): In view of what you said
about the renal consequences of ACE inhibition, do you envi-
sion new tools, utilizing converting enzyme inhibitors, that will
be used to diagnose renal artery stenosis?
DR. BRUNNER: Indeed, the reactive stimulation of renin
secretion in response to ACE inhibition has been used to
identify those hypertensive patients who present with renal
artery stenosis. Case and Laragh have claimed that they could
identify patients with renal artery stenosis by the excessive rise
of peripheral plasma renin activity upon initiation of ACE
inhibition [1921. In our opinion, probably more useful is the fact
that the increased renin secretion accentuates the difference
between the renin levels measured in the vein of the stenosed
kidney and those in the contralateral vein. Furthermore, it is
evident that the observation of progressive renal failure follow-
ing initiation of ACE inhibitor therapy always should lead to an
active search for renal artery stenosis.
DR. CHARLES VAN YPERSELE (Professor of Medicine, Renal
Unit, Cliniques Universitaires St. Luc, Université de Louvain,
Bruxelles, Belgium): Dr. Jaeger's question relates to the diag-
nostic value of captopril renography. Have you experienced, as
we have, ACE-inhibition-induced, reversible renal failure in
patients without renal artery stenosis? Are there any predictive
factors?
DR. BRUNNER: Dr. van Ypersele's comment is very perti-
nent. We also have observed renal failure triggered by ACE
inhibition without any evidence of renal artery stenosis. It is
nevertheless likely that such patients have some vascular
lesions in the periphery of the renal arterial tree that are not
seen on arteriogram. On the other hand, it is also true that a
majority of patients with evidence of either bilateral or unilat-
eral renal artery stenosis do not develop a deterioration of renal
function during ACE inhibition. This should not be surprising
because we are comparing a functional test, that is, the behav-
ior of GFR during ACE inhibition, with a rather crude appre-
ciation of the integrity of the renal vasculature, that is, a renal
artenogram.
Reprint requests to Dr. H. Brunner, Division d'Hypertension, Centre
Hospitalier Universitaire Vaudois, 1011 Lausanne, Suisse
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